Mauritania

Pharmacovigilance in Mauritania is part of the Ministry of Health’s pharmaceutical regulatory and medicine-safety system. Recent French-language national reporting describes ongoing pharmaceutical-sector reforms intended to strengthen regulation, medicine traceability and the national pharmacovigilance system; the Mauritanian state news agency’s report on the réforme du secteur pharmaceutique specifically records the authorities’ work to activate pharmacovigilance and strengthen pharmaceutical oversight. This supports the expectation that suppliers and authorisation holders cooperate with national safety monitoring and report relevant medicine-safety concerns through the competent structures. Importantly, no social-media source is relied upon here. The current publicly accessible national material reviewed does not clearly publish a comprehensive MAH-specific GVP standard defining a mandatory Mauritania-resident QPPV, PSMF, universal numerical ICSR deadline, fixed PSUR/PBRER schedule, standardized RMP requirement, or routine pharmacovigilance-inspection frequency. Those elements should therefore be confirmed directly with the competent Ministry/pharmaceutical authority or from product-specific conditions before being presented as binding requirements. BAUPHARMA supporting resources (operational context only, not national regulatory evidence): Effective Signal Management in Pharmacovigilance.